Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan

Annals of Oncology

Volumn 16, Issue 9, 2005, Pages 1530-1538

  Huang, S Y ^a   Yao, M ^a   Tang, J L ^a   Tsay, W ^a   Lee, F Y ^a   Liu, M C ^a   Wang, C H ^a   Chen, Y C ^a   Shen, M C ^a   Tien, H F ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cytogenetics; Fluorescene in situ hybridization; Multiple myeloma; Prognosis

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CYTOGENETICS; DIPLOIDY; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; TAIWAN; TREATMENT OUTCOME;

EID: 24044505068     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi273     Document Type: Article

References (41)

1. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001; 20: 5611-5622.
2. Zandecki M, Lai JL, Facon T. Multiple myeloma: Almost all patients are cytogenetically abnormal. Br J Haematol 1996; 94: 217-227.
3. Cigudosa JC, Rao PH, Calasanz MJ et al. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 1998; 91: 3007-3010.
4. Sawyer JR, Lukacs JL, Thomas EL et al. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol 2001; 112: 167-174.
5. Nilsson T, Höglund M, Lenhoff S et al. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences. Br J Haematol 2003; 120: 960-969.
6. Debes-Marun CS, Dewald GW, Bryant S et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003; 17: 427-436.
7. Calasanz MJ, Cigudosa JC, Odero MD et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations. Genes Chromosom Cancer 1997; 18: 84-93.
8. Avet-Loiseau H, Facon T, Grosbois B et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002; 99: 2185-2191.
9. Garand R, Avet-Loiseau H, Accard F et al. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003; 17: 2032-2035.
10. Smadja NV, Fruchart C, Isnard F et al. Chromosomal analysis in multiple myeloma: Cytogenetic evidence of two different diseases. Leukemia 1998; 12: 960-969.
11. Fonseca R, Barlogie B, Bataille R et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 2004; 64: 1546-1558.
12. Smadja NV, Bastard C, Brigaudeau C et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98: 2229-2238.
13. Barlogie B, Shaughnessy J, Tricot G et al. Treatment of multiple myeloma. Blood 2004; 103: 20-32.
14. Calasanz MJ, Cigudosa JC, Odero MD et al. Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. Br J Haematol 1997; 98: 418-425.
15. Fonseca R, Harrington D, Oken MM et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (D13) in multiple myeloma: An Eastern Cooperative Oncology Group study. Cancer Res 2002; 62: 715-720.
16. Königsberg R, Zojer N, Ackermann J et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 2000; 18: 804-812.
17. Desikan R, Barlogie B, Sawyer J et al. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
18. Fancon T, Avet-Loiseau H, Guillerm G et al. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-1571.
19. Fassas AB, Spencer T, Sawyer J et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002; 118: 1041-1047.
20. Shaughnessy J, Jacobson J, Sawyer J et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: Interpretation in the context of global gene expression. Blood 2003; 101: 3849-3856.
21. Shaughnessy J Jr, Tian E, Sawyer J et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: Early results of total therapy II. Br J Haematol 2003; 120: 44-52.
22. Tricot G, Barlogie B, Jagannath S et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250-4256.
23. Drach J, Ackermann J, Fritz E et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998; 92: 802-809.
24. Chang H, Sloan S, Li D et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004; 125: 64-68.
25. Johansson B, Mertens F, Mitelman F. Geographic heterogeneity of neoplasia-associated chromosome aberrations. Genes Chromsome Cancer 1991; 3: 1-7.
26. Tien HF, Wang CH, Lin MT et al. Correlation of cytogenetic results with immunophenotype, genotype, clinical features and ras mutation in acute myeloid leukemia: A study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 1995; 84: 60-68.
27. Mitelmen F. Geographic heterogeneity of chromosome aberrations in hematologic disorders. Cancer Genet Cytogenet 1986; 20: 203-208.
28. Chen CY, Yao M, Tang JL et al. Chromosomal abnormalities of 200 Chinese patients with non-Hodgkin's lymphoma in Taiwan: With special reference to T-cell lymphoma. Ann Oncol 2004; 15: 1091-1096.
29. Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 1992; 6: 225-247.
30. Mitelman F (ed.). ISCN. An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S Karger 1995.
31. Ko BS, Tang JL, Lee FY et al. Additional chromosomal abnormalities and variability of BCR breakpoints in Philadelphia chromosome/ BCR-ABL-positive acute lymphoblastic leukemia in Taiwan. Am J Hematol 2002; 71: 291-299
32. Ahmann GJ, Jalal SM, Juneau AL et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet 1998; 101: 7-11.
33. Bladé J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
34. Huang SY, Tang JL, Yao M et al. Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. Ann Hematol 2003; 82: 558-564.
35. Rajkumar SV, Fonseca R, Dewald GW et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999; 113: 73-77.
36. Kaufmann H, Krömer E, Nösslinger T et al. Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma. Eur J Haematol 2003; 71: 179-183.
37. Huang SY, Tien HF, Su FS, Hsu SM. Non-irradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma - a potential in vivo culture system. Am J Pathol 2004; 164: 747-756.
38. Taniwaki M, Nishida K, Takashima T et al. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 1994; 84: 2283-2290.
39. Mellentin JD, Murre C, Donlon TA et al. The gene for enhancer binding proteins E12/E47 lies at the t(1;19) breakpoint in acute leukemias. Science 1989; 246: 379-382.
40. Kaname T, Miyauchi T, Kuwano A et al. Mapping basigin (BSG), a member of the immunoglobulin superfamily, to 19p13.3. Cytogenet Cell Genet 1993; 64: 195-197.
41. Gozzetti A, Davis EM, Espinosa R et al. Identification of novel cryptic translocations involving IGH in B-cell non-Hodgkin's lymphomas. Cancer Res 2002; 62: 5523-5527.